Zeev's Turnips Patch-No Politics (ZEEV)

[jaj1]

I have not follow POZN before but, was thinking the market might be
over reacting to the delay for its migraine drug.

10:15 ET POZEN and GlaxoSmithKline report receipt of approvable letter for investigational migraine treatment (POZN) 13.45 -0.66: -Update- The co and GlaxoSmithKline (GSK) announces the FDA has issued an approvable letter for Trexima. The FDA has determined that Trexima is effective as an acute treatment for migraine headaches. The Agency has requested additional safety information on Trexima, which may require new studies. POZEN and GSK intend to request a meeting with the FDA as quickly as possible to discuss the approvable letter and determine the appropriate next steps to gain full approval. Trexima, the proposed brand name for the product candidate combining sumatriptan 85 mg, as the succinate salt, formulated with RT Technology and naproxen sodium 500 mg in a single tablet, is the first product designed to treat multiple mechanisms of migraine: inflammation and vasodilation. (stock is halted)